Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
PROXIMAL SPLENORENAL SHUNT FOR PORTAL HYPERTENSION COMBINED WITH HYPERSPLENISM IN LIVER CIRRHOSIS Authors: I.Timaru, I.P.O...
<ul><li>CENTRAL SPLENORENAL SHUNT ( LINTON)   =   </li></ul><ul><li>non-selective porto-systemic shunt, achieving:   </li>...
CENTRAL SPLENORENAL SHUNTS: <ul><li>variceal bleeding prophylaxis. </li></ul><ul><li>ONLY INDICATED for  cirrhotic non-enc...
<ul><li>ELECTIVE CRITERIA FOR PATIENT SELECTION: </li></ul><ul><li>CHILD  A  patients </li></ul><ul><li>CHILD  B (with no ...
<ul><li>PATIENT EVALUATION FOR SURGERY </li></ul><ul><li>Clinical evaluation  </li></ul><ul><li>-  hepatic cyrrhosis + por...
<ul><li>DETAILS OF THE CENTRAL SPLENORENAL SHUNTING </li></ul><ul><li>SPLENECTOMY  -  usually difficult (fragile, perisple...
<ul><li>POSTOPERATIVE MONITORING </li></ul><ul><li>Peripheral blood cell count (! Platelets) </li></ul><ul><li>Hepatic and...
<ul><li>SPLENORENAL SHUNT   </li></ul><ul><li>–  CLINICAL OUTCOME CRITERIA  - </li></ul><ul><li>< 20% POSTOPERATIVE DEATHS...
CONCLUSIONS <ul><li>Central (proximal) splenorenal shunt  =  non-selective portal-systemic shunt, valuable for variceal bl...
 
OUR EXPERIENCE <ul><li>1990  -  2002:  17  central splenorenal shunt operations </li></ul><ul><li>17 patients: 14 male,  3...
POSTOPERATIVE OUTCOME <ul><li>Good splenorenal shunt blood flow (sonography measurement), and no shunt thrombosis recorded...
<ul><li>PATIENTS WITH LIVER CIRRHOSIS  </li></ul><ul><li>SHOULD BE ASSIMILATED  </li></ul><ul><li>IN A DATA-BASE NATIONAL ...
Upcoming SlideShare
Loading in …5
×

34

1,453 views

Published on

Published in: Health & Medicine
  • Be the first to comment

34

  1. 1. PROXIMAL SPLENORENAL SHUNT FOR PORTAL HYPERTENSION COMBINED WITH HYPERSPLENISM IN LIVER CIRRHOSIS Authors: I.Timaru, I.P.Oprea, C.Musat, M.Tanase, A.Zaciu, N.Tudor, C.Dutu, R.Nica THE CENTRAL CLINICAL EMERGENCY MILITARY HOSPITAL The 2 nd Surgical Clinic
  2. 2. <ul><li>CENTRAL SPLENORENAL SHUNT ( LINTON) = </li></ul><ul><li>non-selective porto-systemic shunt, achieving: </li></ul><ul><li>A. POSITIVE EFFECTS </li></ul><ul><li>- removes the spleen; </li></ul><ul><li>- lowers portal blood pressure; </li></ul><ul><li>- diminishes gastric and esophageal varices and </li></ul><ul><li>lowers the risk of variceal bleeding; </li></ul><ul><li>- diminution / ascites prophylaxis. </li></ul><ul><li>B. NEGATIVE EFFECTS </li></ul><ul><li>- high risk of hepatic encephalopathy; </li></ul><ul><li>- lowers intrahepatic blood flow, thus, diminishes hepatic function; </li></ul><ul><li>- not convenient for further liver transplantation. </li></ul>
  3. 3. CENTRAL SPLENORENAL SHUNTS: <ul><li>variceal bleeding prophylaxis. </li></ul><ul><li>ONLY INDICATED for cirrhotic non-encephalopathic patients with portal hypertension + splenomegaly and hypersplenism </li></ul><ul><li>+ good liver function (= CHILD A patients) + </li></ul><ul><li>+ mild ascites (= CHILD B patients) </li></ul><ul><li>Alternative procedures: those including splenectomy and </li></ul><ul><li>azygo-portal disconnection. </li></ul>
  4. 4. <ul><li>ELECTIVE CRITERIA FOR PATIENT SELECTION: </li></ul><ul><li>CHILD A patients </li></ul><ul><li>CHILD B (with no hepatic encephalopathy, no jaundice, </li></ul><ul><li>controllable ascites, serum albumin > 3g/dl, PTT > 1.5, </li></ul><ul><li>BSP > 30%) </li></ul><ul><li>Portal hypertension of 3 rd – 4 th degree </li></ul><ul><li>Splenomegaly and hypersplenism (peripheral blood cytopenia, mainly thrombocytopenia) </li></ul><ul><li>Clinical and endoscopy features showing high risk of variceal bleeding </li></ul><ul><li>Age < 60 </li></ul><ul><li>Good nutritional status </li></ul><ul><li>Experienced surgical and anesthesiology team </li></ul><ul><li>The patients are not eligible for liver transplantation. </li></ul>
  5. 5. <ul><li>PATIENT EVALUATION FOR SURGERY </li></ul><ul><li>Clinical evaluation </li></ul><ul><li>- hepatic cyrrhosis + portal hypertension + variceal bleeding </li></ul><ul><li>- nutritional status </li></ul><ul><li>- neurologic assessment. </li></ul><ul><li>Biological evaluation </li></ul><ul><li>- hepatic function status </li></ul><ul><li>- biliary excretion (bilirubinemia, alcalin phosphatase) </li></ul><ul><li>- peripheral blood and bone marrow cell count </li></ul><ul><li>- renal function. </li></ul><ul><li>Esophago-gastric endoscopy (variceal status) </li></ul><ul><li>Doppler ultrasonography (portal, splenic, mesenteric, renal, caval flow and diametres) </li></ul><ul><li>Selective arteriography (truncus coeliacus, renal arteries), left renal venography </li></ul><ul><li>Radioisotopic portography (portal blood flow, porto-systemic shunts, hepatic shunts, splenic fraction shunt) </li></ul><ul><li>Excretory urography. </li></ul>
  6. 6. <ul><li>DETAILS OF THE CENTRAL SPLENORENAL SHUNTING </li></ul><ul><li>SPLENECTOMY - usually difficult (fragile, perisplenic vascular adhesions, collateral portal circulation, anatomic variations in the hilum) </li></ul><ul><li>SPLENIC VEIN DISSECTION </li></ul><ul><li>LEFT RENAL VEIN DISSECTION </li></ul><ul><li>SPLENORENAL ANASTOMOSIS (end-to-side, side-to-side, end-to-end) </li></ul><ul><li>ASSESSMENT: intraoperative Doppler sonography, diminution of portal circulation (omentum, phrenic vessels), measurement of portal blood pressure. </li></ul>
  7. 7. <ul><li>POSTOPERATIVE MONITORING </li></ul><ul><li>Peripheral blood cell count (! Platelets) </li></ul><ul><li>Hepatic and renal function </li></ul><ul><li>Ultrasonography </li></ul><ul><li>Esophageal and gastric endoscopy </li></ul><ul><li>POSTOPERATIVE MORBIDITY </li></ul><ul><li>Postoperative bleeding </li></ul><ul><li>Surgical wound / systemic sepsis </li></ul><ul><li>Shunt thrombosis </li></ul><ul><li>Splenic / portal thrombosis </li></ul><ul><li>Acute pancreatitis </li></ul><ul><li>Hepatic failure </li></ul><ul><li>Hepatic encephalopathy </li></ul><ul><li>Renal failure </li></ul>
  8. 8. <ul><li>SPLENORENAL SHUNT </li></ul><ul><li>– CLINICAL OUTCOME CRITERIA - </li></ul><ul><li>< 20% POSTOPERATIVE DEATHS </li></ul><ul><li>HEPATIC ENCEPHALOPATHY </li></ul><ul><li>RECURRENT VARICEAL BLEEDING (due to shunt thrombosis ~ 18%) </li></ul><ul><li>PATIENT SURVIVAL IMPROVEMENT </li></ul>
  9. 9. CONCLUSIONS <ul><li>Central (proximal) splenorenal shunt = non-selective portal-systemic shunt, valuable for variceal bleeding prophylaxis, in selected patients. </li></ul><ul><li>The surgical procedure must be well prepared; the eligible patients will be thoroughly investigated to match the proper criteria. </li></ul><ul><li>Postoperative complications are usually severe. </li></ul><ul><li>The postoperative clinical outcome is similar to azygo-portal disconnection and splenectomy, and inferior to selective shunts (calibrated portacaval /mesenterocaval shunts, Warren operation). </li></ul>
  10. 11. OUR EXPERIENCE <ul><li>1990 - 2002: 17 central splenorenal shunt operations </li></ul><ul><li>17 patients: 14 male, 3 female </li></ul><ul><li>Age: 36 – 54 (avg. 43) </li></ul><ul><li>Viral hepatic cirrhosis (B and C) - 14 patients </li></ul><ul><li>Alcoholic cirrhosis - 3 patients </li></ul><ul><li>Mild ascites - 7 patients </li></ul><ul><li>Esophageal varices - stage III - 10 patients </li></ul><ul><li>- stage IV - 7 patients </li></ul><ul><li>Child-Pugh score - A - 10 patients </li></ul><ul><li>- B - 7 patients </li></ul>
  11. 12. POSTOPERATIVE OUTCOME <ul><li>Good splenorenal shunt blood flow (sonography measurement), and no shunt thrombosis recorded. </li></ul><ul><li>Hepatic failure (coagulation disorders, jaundice, hepatocyte lysis) </li></ul><ul><li>- 5 patients </li></ul><ul><li>Hepatic encephalopathy - permanent - 3 patients </li></ul><ul><li>- temporary - 7 patients </li></ul><ul><li>Thrombocytosis (due to splenectomy) – started 3 rd – till 10 th day P.O. </li></ul><ul><li>required thrombosis prophylaxis: </li></ul><ul><li>- < 500.000 platelets/sqmm. – 14 patients (l.m.w. heparin fractions) </li></ul><ul><li>- > 500.000 platelets/sqmm. (up to 1.2 mil.) – 3 patients (heparin) </li></ul><ul><li>Variceal bleeding - free survival: min. 9 months (recurrent alcohol ingestion), max. 2 years . </li></ul><ul><li>Survival period (for 8 patients) - 2 yrs.8 mon. – 11 yrs. </li></ul>
  12. 13. <ul><li>PATIENTS WITH LIVER CIRRHOSIS </li></ul><ul><li>SHOULD BE ASSIMILATED </li></ul><ul><li>IN A DATA-BASE NATIONAL PROGRAM. </li></ul>

×